Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.21 USD | -1.78% | -16.60% | +72.66% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 145M |
---|---|---|---|---|---|
Net income 2024 * | -34M | Net income 2025 * | -47M | EV / Sales 2024 * | - |
Net cash position 2024 * | 84.8M | Net cash position 2025 * | 51.3M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-3.71
x | P/E ratio 2025 * |
-3.15
x | Employees | 30 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.99% |
Latest transcript on Regulus Therapeutics Inc.
1 day | -1.78% | ||
1 week | -16.60% | ||
Current month | -3.91% | ||
1 month | -21.07% | ||
3 months | +33.94% | ||
6 months | +67.42% | ||
Current year | +72.66% |
Managers | Title | Age | Since |
---|---|---|---|
Joseph Hagan
CEO | Chief Executive Officer | 55 | 16-01-03 |
Preston Klassen
PSD | President | 55 | 23-06-21 |
Crispina Calsada
DFI | Director of Finance/CFO | 54 | 19-08-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pascale Witz
BRD | Director/Board Member | 57 | 17-05-31 |
David Baltimore
BRD | Director/Board Member | 86 | 08-12-31 |
Director/Board Member | 76 | 13-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 2.21 | -1.78% | 659,058 |
24-05-09 | 2.25 | -0.88% | 613,612 |
24-05-08 | 2.27 | +1.79% | 446,129 |
24-05-07 | 2.23 | -8.23% | 704,792 |
24-05-06 | 2.43 | -8.30% | 891,189 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+72.66% | 145M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- RGLS Stock